Curious about Edwards Lifesciences (EW) Q2 Performance? Explore Wall Street Estimates for Key Metrics

Core Insights - Analysts forecast Edwards Lifesciences (EW) to report quarterly earnings of $0.62 per share, reflecting a year-over-year decline of 11.4% [1] - Expected revenues are projected at $1.49 billion, indicating a decrease of 8.9% compared to the same quarter last year [1] Earnings Estimates - The consensus EPS estimate has remained unchanged over the last 30 days, indicating a collective reevaluation by analysts [2] - Changes in earnings estimates are crucial for predicting investor reactions, with empirical studies showing a strong relationship between earnings estimate revisions and short-term stock price performance [3] Key Metrics Projections - Net Sales by Product Group for Transcatheter Mitral and Tricuspid Therapies is estimated at $129.87 million, a change of +56.5% from the year-ago quarter [5] - Net Sales by Product Group for Surgical Structural Heart is projected at $259.33 million, reflecting a decrease of -1.9% from the previous year [5] - Net Sales by Product Group for Transcatheter Aortic Valve Replacement is expected to be $1.10 billion, showing an increase of +5.7% year-over-year [6] - Net Sales in Europe are anticipated to reach $353.07 million, indicating a change of +5.2% from the prior-year quarter [6] Regional Sales Expectations - Net Sales Outside of the United States are projected at $621.76 million, reflecting a change of +9.3% from the year-ago quarter [7] - Net Sales in the United States are expected to be $865.54 million, indicating a change of +6% year-over-year [7] - Net Sales in Japan are forecasted to reach $105.11 million, showing an increase of +20.3% from the prior-year quarter [7] - Net Sales for the Rest of World are projected at $163.59 million, reflecting a change of +12% from the previous year [8] Stock Performance - Edwards Lifesciences shares have increased by +3.6% in the past month, compared to the Zacks S&P 500 composite's +5.4% [8] - With a Zacks Rank 2 (Buy), EW is expected to outperform the overall market performance in the near term [8]